HopeStage
Back to all studies
CompletedEUCTR 2005-002304-41

Early versus late initiation of treatment with Risperdal Consta in subjects with schizophrenia or schizoaffective disorder after an acute episode

This historical record does not confirm current site availability.

Historical research recordMultiple countries
The study in practice

Understand this study

What did researchers investigate?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Who was this study for?

This study was for people with schizophrenia. Other eligibility criteria applied.

Listed locations
Denmark · Finland and 4 more locations
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateNot clearly listed
Recruitment status
Completed
Enrollment listed in the registry
220
Sponsor
Janssen-Cilag EMEA Medical Affairs
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United Kingdom, Denmark, Finland, ...
Age range
Not clearly listed
Official registry ID
EUCTR 2005-002304-41
Official title
Show the full official title

Early versus late initiation of treatment with Risperdal Consta in subjects with schizophrenia or schizoaffective disorder after an acute episode

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Denmark · Finland · Italy

3 more locations
  • Slovenia
  • Sweden
  • United Kingdom
Registry details
Historical country statuses

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Janssen-Cilag EMEA Medical Affairs.

Who was this study for?

This study was for people with schizophrenia. Other eligibility criteria applied.

Want to explore more studies?

Explore studies